Meloxicam SBEβCD Composition for Faster Oral Absorption
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Meloxicam, a nonsteroidal anti-inflammatory drug, has poor aqueous solubility, leading to reduced bioavailability and slow onset of pain relief.
Innovation Solution
Formulating meloxicam with sulfobutyl ether β-cyclodextrin (SBEβCD) and bicarbonate to create an inclusion complex, enhancing solubility and bioavailability, and combining it with rizatriptan for rapid and sustained pain relief.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Stability of the object's composition
If meloxicam is used as a conventional NSAID formulation, then it provides anti-inflammatory and analgesic activities, but it has poor aqueous solubility which reduces bioavailability and slows onset of pain relief
Solution Approach 1:
The patent uses cyclodextrins as intermediary carrier molecules that form inclusion complexes with meloxicam. The cyclodextrin's hydrophobic interior cavity accommodates the meloxicam molecule while the hydrophilic exterior enables aqueous solubility, thus mediating between the insoluble drug and the aqueous environment to improve bioavailability and accelerate onset of action
Solution Approach 2:
The patent creates a composite pharmaceutical formulation consisting of meloxicam combined with cyclodextrin derivatives (such as sulfobutyl ether β-cyclodextrin). This composite material integrates the therapeutic properties of meloxicam with the solubility-enhancing properties of cyclodextrin, resulting in a formulation with superior aqueous solubility and bioavailability compared to conventional meloxicam alone
2Speed
If meloxicam is used as a conventional NSAID formulation, then it provides anti-inflammatory activities, but it has slow onset of pain relief
Solution Approach 1:
Cyclodextrin acts as a mediator that facilitates rapid dissolution and absorption of meloxicam by forming soluble inclusion complexes in the gastrointestinal tract, thereby accelerating the onset of pain relief without compromising the stability of the drug molecule
Solution Approach 2:
The patent modifies the physical-chemical parameters of meloxicam by complexing it with cyclodextrin, changing its solubility characteristics and absorption kinetics. This parameter change enables faster dissolution and quicker onset of analgesic effect while maintaining the drug's therapeutic stability
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The combination significantly increases meloxicam's oral bioavailability and absorption rate, providing rapid and sustained relief from migraine and other pain conditions, reducing the need for rescue medication and improving treatment outcomes.
Implementation Method 1
In aqueous solutions, cyclodextrins can form complexes (i.e., an inclusion complex) with drugs by incorporating the drug into the center/hydrophobic portion of the cyclodextrin ring
Implementation Method 2
Cyclodextrins are hydrophobic on the inside and hydrophilic on the inside which helps to facilitate the transport of molecules
Data Source
AI summary
Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.